Dexamethasone tablets

DRUG3 trials

Sponsors

National Cancer Institute (NCI), pharmaand GmbH, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Carcinoma, Non-Small-Cell LungMultiple Myeloma

Phase 1

Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer

TerminatedNCT00923273

National Cancer Institute (NCI)Carcinoma, Non-Small-Cell Lung

Start: 2008-02-29End: 2013-03-10Updated: 2019-11-26

Phase 2

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

CompletedNCT02654990

pharmaand GmbHMultiple Myeloma

Start: 2016-04-27End: 2022-08-15Updated: 2024-07-12

Phase 3

Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

Not yet recruitingNCT07569757

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Multiple Myeloma

Start: 2026-06-01End: 2030-12-01Target: 260Updated: 2026-05-08

Related Papers

Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease

Blood2021-11-05

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.

2020-12-0742 citations

Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study

Blood2020-11-054 citations

A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer

Translational Lung Cancer Research2019-06-0115 citations